BIOTECH FIRMS CHASE 'ORPHAN' DRUGS

A A

More drug companies are embracing the challenge of creating therapies for rare diseases, despite the small potential markets for those drugs. Last week, for example, Genzyme, a company based in Cambridge, Massachusetts, received approval from the Food and Drug Administration to sell an intravenous drug to treat a rare neuromuscular disease that afflicts no more than 10,000 worldwide.

International Herald Tribune (http://www.iht.com/articles/2006/05/01/business/drug.php)